Abstract
Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a Lysa Multicenter, Phase II Study. “the TOTAL Trial”
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have